Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed-Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions-Data From 2 Single-Center, Single-Dose, Randomized Crossover Studies in Healthy Volunteers.
Weiser T, Schepers C, Mück T, Lange R. Weiser T, et al. Among authors: schepers c. Clin Pharmacol Drug Dev. 2019 Aug;8(6):742-753. doi: 10.1002/cpdd.672. Epub 2019 Mar 21. Clin Pharmacol Drug Dev. 2019. PMID: 30897305 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
Bianzano S, Heise T, Jungnik A, Schepers C, Schölch C, Gräfe-Mody U. Bianzano S, et al. Among authors: schepers c. Clin Diabetes Endocrinol. 2021 Aug 15;7(1):16. doi: 10.1186/s40842-021-00130-x. Clin Diabetes Endocrinol. 2021. PMID: 34391480 Free PMC article.
Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days.
Bianzano S, Schepers C, Wolff M, Heise T, Plum-Moerschel L. Bianzano S, et al. Among authors: schepers c. Exp Clin Endocrinol Diabetes. 2022 Dec;130(12):773-782. doi: 10.1055/a-1932-3136. Epub 2022 Nov 7. Exp Clin Endocrinol Diabetes. 2022. PMID: 36343645 Free PMC article. Clinical Trial.
Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials.
Lv Q, Shen J, Miao L, Ye B, Schepers C, Plat A, Shi Y. Lv Q, et al. Among authors: schepers c. Diabetes Ther. 2020 Jun;11(6):1317-1330. doi: 10.1007/s13300-020-00819-9. Epub 2020 Apr 23. Diabetes Ther. 2020. PMID: 32328953 Free PMC article.
21 results